Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of endoscopic transorbital approach for skull base and orbital lesionsNew Eye Socket Surgery Cuts Recovery Time Without Raising Risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ETOA for skull base and orbital lesions with low reported complication rates in this meta-analysis.

This systematic review and meta-analysis examines the endoscopic transorbital approach (ETOA) as a surgical modality for patients with skull base and orbital lesions. The analysis included 269 patients who underwent ETOA as the sole surgical technique. Follow-up duration was 27.6 ± 15.1 months across the included studies.

The meta-analysis reports specific complication rates for secondary outcomes. CSF leak occurred in 1% of cases (95% CI: 0.00 to 0.04). Wound infection was observed in 3% (95% CI: 0.01 to 0.07). Other complications included ptosis in 4% (95% CI: 0.00 to 0.14), diplopia in 6% (95% CI: 0.01 to 0.14), and medial gaze palsy in 9% (95% CI: 0.04 to 0.18).

Visual outcomes showed improvement in 47% of cases (95% CI: 0.22 to 0.73) while visual dysfunction occurred in 1% (95% CI: 0.00 to 0.04). Transient facial numbness was reported in 16% (95% CI: 0.09 to 0.25). Mortality was 0% (95% CI: 0.00 to 0.02). The authors conclude that ETOA is a safe and promising technique for managing a wide range of skull base and orbital lesions.

The authors acknowledge that future prospective and comparative studies are needed to refine indications and validate long-term efficacy. Funding or conflicts of interest were not reported. The certainty of the evidence is not explicitly graded in the source text.

Imagine needing brain surgery. The thought alone is scary. Now imagine waking up with no large scar on your head and going home in days instead of weeks.

That possibility is getting closer. A new review of 269 patients shows that a surgery called the endoscopic transorbital approach (ETOA) is safe and effective. It enters the skull through the eye socket.

This matters because brain surgery has traditionally meant large incisions, long hospital stays, and slow recovery. Patients and their families have been looking for a better way.

This doesn't mean this treatment is available everywhere yet.

Who needs this surgery

Brain tumors and growths behind the eye affect thousands of people each year. These growths can press on nerves, cause vision problems, and lead to headaches or facial pain.

The most common tumor treated with this approach is meningioma. It made up over 60 percent of cases in the review. Other growths included schwannomas and cavernous hemangiomas.

Traditional surgery for these growths often requires opening a large section of the skull. That means more pain, more risk of infection, and a longer recovery.

A new path to the brain

The old way of thinking said you needed a big opening to reach the brain safely. Surgeons would cut through the scalp, remove a piece of bone, and work through that window.

But here is the twist. The endoscopic transorbital approach uses a small camera and tools that go through the eye socket. Think of it like using a tiny flashlight and long tweezers through a keyhole instead of taking down the whole door.

This approach avoids cutting through the skull bone. It also avoids touching the brain's surface directly. That means less trauma to healthy tissue.

Surgeons make a small cut inside the eyelid or along the eyebrow. They insert a thin tube with a camera on the end. This camera gives them a clear view of the area behind the eye and the base of the skull.

They can then remove tumors or growths using tiny instruments. The whole process takes less time than traditional surgery. Patients often go home within a few days.

The camera provides high-definition images. Surgeons can see nerves, blood vessels, and the tumor clearly. This helps them avoid damaging important structures.

The review looked at 11 studies with 269 patients. The average follow-up time was about 27 months. That is over two years of checking on patients after surgery.

The results are encouraging. No patients died from the surgery. That is a zero percent death rate.

Serious complications were rare. Only 1 percent of patients had a spinal fluid leak. Only 3 percent had a wound infection. These numbers are similar to or better than traditional skull surgery.

The vision benefits

Nearly half of patients (47 percent) saw improvement in their vision after surgery. This is a big deal because many of these growths press on the optic nerve.

Only 1 percent of patients had new vision problems after surgery. That means the surgery is good at protecting eyesight while removing the growth.

Some patients had temporary side effects. About 16 percent had facial numbness that went away. About 6 percent had double vision. These issues often resolved on their own.

But there is a catch

The numbers look good. But this is still a new technique. Only 269 patients have been studied in this review. That is a small number compared to traditional surgery.

Also, the studies were observational. That means they did not compare ETOA directly to standard surgery in a controlled trial. We need more research to know for sure which approach is better.

The surgeons who performed these procedures were highly trained specialists. Results may not be the same at every hospital.

What this means for patients

If you or a loved one has a brain tumor or growth behind the eye, this approach may be an option. But it is not right for everyone.

The location and size of the growth matter. Some tumors are too large or in hard-to-reach places for this technique. Your surgeon will need to evaluate your specific case.

Ask your doctor about ETOA if you are facing surgery for a skull base or orbital growth. Not all hospitals offer this approach yet. You may need to travel to a specialized center.

What happens next

Researchers are planning larger studies that compare ETOA directly to traditional surgery. These studies will help doctors know exactly which patients benefit most.

The technique is still evolving. Surgeons are finding new ways to use it and improve it. More training programs are teaching this approach to new surgeons.

For now, the evidence suggests this is a safe and promising option. But like all medical advances, it takes time to prove its full value. The next few years will bring more answers.

Study Details

Study typeMeta analysis
Sample sizen = 5
EvidenceLevel 1
Follow-up15.1 mo
PublishedMay 2026
View Original Abstract ↓
Endoscopic techniques have enabled minimally invasive approaches in neurosurgery, providing shorter recovery times and favorable outcomes. Among these, the endoscopic transorbital approach (ETOA) has emerged as a versatile surgical modality. Despite the growing body of evidence, complication rates associated with ETOA have not yet been systematically evaluated. We systematically searched PubMed, Embase, Scopus, and Web of Science up to March 2026. We included studies enrolling ≥ 5 patients who underwent ETOA as the sole surgical modality to treat both skull base and orbital lesions, providing data on early or long-term complications. A single-group meta-analysis was performed using a random-effects model with 95% confidence intervals. Heterogeneity was assessed with the I² statistic and further explored through Baujat plots and sensitivity analyses. A total of 11 observational studies, comprising 269 patients, were included. Overall, 21 different pathologies were reported. Meningioma represented the most frequent lesion (60.6% of cases), followed by schwannoma (12.0%), cavernous hemangioma (4.6%), and glioma (2.7%). Mean follow-up was 27.6 ± 15.1 months. CSF leak was observed in 1% (95% CI: 0.00 to 0.04, I² = 46.5%), and wound infection was observed in 3% (95% CI: 0.01 to 0.07, I²=0%). Ptosis occurred in 4% (95% CI: 0.00 to 0.14, I²=79.4%) and diplopia occurred in 6% (95% CI: 0.01 to 0.14, I²=68.9%). Medial gaze palsy occurred in 9% (95% CI: 0.04 to 0.18, I²=8.8%). Improvement in visual function was seen in 47% (95% CI: 0.22 to 0.73, I²=88.7%). Visual dysfunction occurred in 1% (95% CI: 0.00 to 0.04, I²=48.6%). Transient facial numbness occurred in 16% (95% CI: 0.09 to 0.25, I²=35.0%). Mortality was 0% (95% CI: 0.00 to 0.02, I²=28.7%). ETOA is a safe and promising technique for managing a wide range of skull base and orbital lesions. Future prospective and comparative studies are needed to refine indications and validate its long-term efficacy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.